Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Benzinga · 2d ago
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.